POZEN AND ASTRAZENECA ANNOUNCE GLOBAL COLLABORATION TO CO-DEVELOP AND COMMERCIALIZE FIXED DOSE COMBINATIONS OF NAPROXEN AND ESOMEPRAZOLE FOR THE TREATMENT OF PAIN

POZEN Inc. announced that it has signed an exclusive global collaboration agreement with AstraZeneca for the co-development and commercialization of proprietary fixed dose combinations of the proton pump inhibitor (PPI) esomeprazole magnesium, with the non-steroidal anti-inflammatory drug (NSAID) naproxen, in a single tablet.

Biotech Intelligence (http://www.biotech-intelligence.com/html/html/pool_3/d6be44e4acecfd383562a8279afc4abf.html)